TickerFacts.

ARS Pharmaceuticals, Inc. (SPRY): Long-Term Debt

Annual figures by period end, from SEC filings.

$96.37M
As of 2025-12-31
$96.68M
As of 2026-06-30
2024-12-31: $02025-12-31: $96.37M$96.37M
2024-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$96.37Mn/a2026-03-09, Balance as of period end
2024-12-31$0n/a2026-03-09, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
ARS Pharmaceuticals, Inc. (SPRY)2025-12-31$96.37Mn/a
Standard Biotools Inc. (LAB)2024-12-31$299.0K-99.5%
Cytokinetics Inc (CYTK)2024-12-31$619.52M-3.1%
Eton Pharmaceuticals, Inc. (ETON)2024-12-31$29.81Mn/a
Kura Oncology, Inc. (KURA)2025-12-31$9.70M+1.9%
Zevra Therapeutics, Inc. (ZVRA)2025-12-31$61.93M+4.1%
UroGen Pharma Ltd. (URGN)2025-12-31$125.00Mn/a
Fortress Biotech, Inc. (FBIO)2025-12-31$52.42M-9.6%
Nuvation Bio Inc. (NUVB)2025-12-31$47.21Mn/a

Compare SPRY, LAB, CYTK, ETON side by side · Screen every company in Pharmaceutical Preparations ↗